EA201401133A1 - PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS); - Google Patents
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS);Info
- Publication number
- EA201401133A1 EA201401133A1 EA201401133A EA201401133A EA201401133A1 EA 201401133 A1 EA201401133 A1 EA 201401133A1 EA 201401133 A EA201401133 A EA 201401133A EA 201401133 A EA201401133 A EA 201401133A EA 201401133 A1 EA201401133 A1 EA 201401133A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- prevention
- treatment
- overweight
- obesity
- disorders associated
- Prior art date
Links
Abstract
Предложены композиции и наборы для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, содержащие ингибиторы дипептидилпептидазы IV (ДПП-IV), метформин и сибутрамин или их фармацевтически приемлемые соли в качестве активных компонентов. Изобретение относится также к применению композиций и наборов для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, в том числе при сахарном диабете II типа, и к способу профилактики и лечения нарушений, связанных с избыточным весом или ожирением, в том числе при сахарном диабете II типа. Композиции обладают выраженным синергетическим эффектом, который проявляется в значительном снижении веса и побочных явлений, а также снижении уровня глюкозы в крови при совместном применении в составе композиций вилдаглиптина или саксаглиптина, метформина и сибутрамина при нарушениях, связанных с избыточным весом или ожирением, в том числе при сахарном диабете II типа.Proposed compositions and kits for the prevention and treatment of disorders associated with overweight or obesity, containing inhibitors of dipeptidyl peptidase IV (DPP-IV), metformin and sibutramine or their pharmaceutically acceptable salts as active ingredients. The invention relates also to the use of compositions and kits for the prevention and treatment of disorders associated with overweight or obesity, including diabetes mellitus type II, and to a method for the prevention and treatment of disorders associated with overweight or obesity, including sugar type II diabetes. The compositions have a pronounced synergistic effect, which is manifested in a significant reduction in weight and side effects, as well as a decrease in blood glucose levels when vildagliptin or saxagliptin, metformin and sibutramine are used in combination with overweight or obesity, including type II diabetes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201401133A EA023747B1 (en) | 2014-11-13 | 2014-11-13 | Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201401133A EA023747B1 (en) | 2014-11-13 | 2014-11-13 | Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201401133A1 true EA201401133A1 (en) | 2016-02-29 |
EA023747B1 EA023747B1 (en) | 2016-07-29 |
Family
ID=55404353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201401133A EA023747B1 (en) | 2014-11-13 | 2014-11-13 | Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA023747B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114028370A (en) * | 2021-11-10 | 2022-02-11 | 中山大学 | Composition with effects of preventing and treating obesity and related diseases and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20100156A1 (en) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | NAFLD TREATMENT |
DK2498758T3 (en) * | 2009-11-13 | 2018-10-15 | Astrazeneca Ab | TWO-LAYER TABLET FORMULATIONS |
EP2498757A1 (en) * | 2009-11-13 | 2012-09-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
-
2014
- 2014-11-13 EA EA201401133A patent/EA023747B1/en active IP Right Revival
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114028370A (en) * | 2021-11-10 | 2022-02-11 | 中山大学 | Composition with effects of preventing and treating obesity and related diseases and application thereof |
CN114028370B (en) * | 2021-11-10 | 2023-10-24 | 中山大学 | Composition with effects of preventing and treating obesity and related diseases and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EA023747B1 (en) | 2016-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000586A (en) | Treatment of amd using aav sflt-1. | |
EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
EA201490377A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKVINIMODE AND GLATIRAMER ACETATE | |
EA201491773A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODE AND DIMETYL FUMARATE | |
EA201391033A1 (en) | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | |
EA201100440A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS OF THEIR APPLICATION FOR CORRECTION OF URIC ACID LEVEL | |
PH12017500453B1 (en) | Spirocyclic inhibitors of cathepsin c | |
BR112013029256A2 (en) | "Pharmaceutical combinations for use in the treatment of patients with type 2 diabetes, treatment method, and uses of lixisenatide and metformin." | |
EA201390984A1 (en) | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | |
MY165122A (en) | Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same | |
MX2017004772A (en) | Compositions and methods for physiological delivery using cannabidiol. | |
AR091724A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION | |
MX2011012310A (en) | Treatment of heart failure with normal ejection fraction. | |
EA201490516A1 (en) | BIFENILKARBOXYAMIDES AS ROCK KINAZ INHIBITORS | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
MA32416B1 (en) | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYMETHYL-AND 7-SULFONYLMETHYL-INDOLES AND THEIR USE | |
EA201401133A1 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS); | |
NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
IN2014DN09240A (en) | ||
NZ702666A (en) | A method of weight reduction | |
UY36354A (en) | AROMATIC COMPOUNDS REPLACED AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | |
BR112015020566A2 (en) | ror gamma modulators | |
EA201301352A1 (en) | Pharmaceutical compositions and kits for preventing and treating disorders associated with being overweight or obese, their use and method for prophylaxis and treatment of disorders associated with being overweight or obese | |
WO2013100660A3 (en) | Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor | |
IN2014MU00187A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): AM AZ BY KZ RU |